Related Experiment Video
Updated: Jun 19, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Anticoagulation in nonvalvular atrial fibrillation
Bipinpreet S Nagra1, Bharat K Kantharia
1Albert Einstein Medical Center, Division of Cardiac Electrophysiology 5501 Old York Road, Levy 3-East, Philadelphia, PA 19118, USA. nagrab@einstein.edu
Insights
Atrial fibrillation, a common heart rhythm disorder, significantly raises stroke risk. This review examines oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation, focusing on risk assessment tools.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Atrial fibrillation is a prevalent cardiac arrhythmia, increasing ischemic stroke risk fivefold.
- Nonvalvular atrial fibrillation accounts for 15-20% of all strokes.
- Stroke prevention in atrial fibrillation relies on antiplatelet agents and oral anticoagulants.
Purpose of the Study:
- To review the risks and benefits of oral anticoagulants in nonvalvular atrial fibrillation.
- To emphasize accurate risk stratification tools for ischemic stroke in this patient population.
Main Methods:
- Literature review of studies on oral anticoagulants and stroke prevention in nonvalvular atrial fibrillation.
- Analysis of risk stratification tools for ischemic stroke.
Main Results:
- Oral anticoagulants are effective in reducing stroke risk.
- Accurate risk stratification is crucial for optimal treatment selection.
- Potential risks associated with oral anticoagulants must be carefully weighed against benefits.
Conclusions:
- Oral anticoagulants are a cornerstone of stroke prevention in nonvalvular atrial fibrillation.
- Effective risk stratification is essential for personalized treatment strategies.
- Balancing efficacy and safety is paramount in managing anticoagulation for stroke prevention.
Abstract:
Atrial fibrillation is the most common, serious, cardiac arrhythmia and increases the risk for ischemic stroke fivefold. Nonvalvular atrial fibrillation may be responsible for up to 15-20% of strokes. Antiplatelet agents and oral anticoagulants are used for stroke prevention in atrial fibrillation. The following review article discusses the potential risks and benefits of oral anticoagulants in nonvalvular atrial fibrillation with particular emphasis on accurate risk stratification tools for ischemic stroke.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Aortic Regurgitation III: Medical Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

